Compare Annaly Capital Management, Inc. (NLY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Annaly Capital Management, Inc. trades at $23.11 (market cap $17.44B), while Regeneron Pharmaceuticals Inc trades at $797 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.7× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (12.96%). Which is the better fit depends on your goals.
| NLY | REGN | |
|---|---|---|
Market Cap | $17.44B | $82.06B |
Sector | Financials | Health |
52-Week High | $24.40 | $812.27 |
52-Week Low | $20.21 | $555.51 |
Dividend Yield | 12.96% | 0.47% |
Enterprise Value | — | $76.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $23.23, up 1.4% with strong technical momentum as moving averages signal bullish sentiment. The stock demonstrates robust fundamentals with a low P/E of 5.59 and impressive 92.77% net income margin, supported by three consecutive quarterly earnings beats. Recent analyst upgrades and institutional buying reflect growing confidence in the mortgage REIT's housing finance strategy and dividend sustainability.
Outlook remains positive with consensus price target of $24.50 offering 5.5% upside potential. Key opportunities include the 13%+ dividend yield and diversified housing finance platform, while risks center on interest rate volatility and the company's high leverage ratio of 23.55. Earnings growth momentum and institutional support provide catalysts for continued appreciation.
Regeneron Pharmaceuticals (REGN) trades at $797.99, down 1.24% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with a 27.86% net income margin and consistent earnings beats, though revenue growth is modest. Recent news highlights a class action lawsuit related to clinical trial disclosures, creating near-term sentiment headwinds despite positive analyst coverage.
Outlook remains supported by robust profitability and a bullish analyst consensus, but risks include legal overhangs and potential volatility from trial outcomes. The stock's valuation at a P/E of 19.72 appears reasonable given earnings strength, though investors should weigh litigation risks against fundamental resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
